• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Scientists Cite Concerns Over “Unlikely” Patterns in Phase 1/2 Trial Data of Russia’s COVID-19 Vaccine

Scientists Cite Concerns Over “Unlikely” Patterns in Phase 1/2 Trial Data of Russia’s COVID-19 Vaccine

September 14, 2020

The reliability of early-stage trial results of Russia’s COVID-19 vaccine, Sputnik-V, are being called into question in an open letter penned by a team of 26 scientists. These scientists are saying they observe patterns in the study data that look “highly unlikely,” including reports that several participants receiving the experimental vaccine in the study had identical antibody levels.

The scientists, most of whom are from universities in Italy, addressed their concerns to the editor of The Lancet, the journal that published Russia’s early-stage trial results of its vaccine. The concerns were based on the published summary of the trial data rather than the original data itself.

Moscow’s Gamaleya Institute, which developed Sputnik-V, has publicly rejected the criticism, saying “the published results are authentic and accurate” and were assessed by five Lancet reviewers. The institute rebukes the open letter by noting it had submitted the raw trial data to the journal in their entirety.

This isn’t the first time Sputnik-V has drawn criticism from global scientists. In early August, the vaccine candidate was approved by Russian health regulators before large-scale phase 3 trials of the vaccine had been conducted. Since then, the Gamaleya Institute has launched a 40,000-participant phase 3 trial of the vaccine. So far, approximately 31,000 patients have enrolled in that trial.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing